Apremilast in the Management of Disseminated Granuloma Annulare-Reference-Cited by-同舟云学术

Apremilast in the Management of Disseminated Granuloma Annulare

Published:2021-05-09 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Joshi Tejas P,Tschen Jaime

Publisher

Cureus, Inc.

Subject

Aerospace Engineering

Reference11 articles.

1. Etiology, diagnosis, and therapeutic management of granuloma annulare: an update;Thornsberry LA;Am J Clin Dermatol,2013

2. Granuloma annulare: a focused review of therapeutic options;Wang J;Am J Clin Dermatol,2018

3. FDA. Otezla (apremilast) tablets, for oral use. (2014). Accessed: February 14, 2021: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205437s000lbl.pdf.

4. Off-label studies on apremilast in dermatology: a review;Maloney NJ;J Dermatolog Treat,2020

5. Granuloma annulare;Little EG;Br J Dermatol,1908

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to “Atopic comorbidities associated with granuloma annulare: A case-control study of the All of Us database”;Journal of the American Academy of Dermatology;2023-11

2. Heterogenous cytokine profiles in patients with granuloma annulare may indicate immune dysregulation spanning multiple T-cell axes;Journal of the American Academy of Dermatology;2023-11

3. PDE4 inhibitors for disease therapy: advances and future perspective;Future Medicinal Chemistry;2023-07

4. Evolving utility of apremilast in dermatological disorders for off-label indications;Clinical and Experimental Dermatology;2022-12-01

5. Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options;American Journal of Clinical Dermatology;2021-09-08